Fc Engineered Anti-Human CD52 Therapeutic Antibody, a CDC-Enhanced Biobetter [Lot: CB20-PZ22] (CAT#: BioBet-C022ZP) Datasheet

Target
CD52
Isotype
Whole Humanized Antibody
Description
CDC-enhanced Alemtuzumabis a Fc-modified anti-CD52 therapeutic biobetter. Creative Biolabs' advanced CDC-enhanced antibody platform allows for the production of Fc engineered therapeutic CDC⁺ antibodies. By mutating key amino acids of the Fc region of Alemtuzumab, the Fc region of Alemtuzumab exhibits a greater binding capacity to C1q, thereby achieving enhanced CDC activity.
Indication
Autoimmune Hemolytic Anemia
B-Cell Chronic Lymphocytic Leukemia
Graft Versus Host Disease (GVHD)
Kidney Transplant Rejection
Relapsing Remitting Multiple Sclerosis (RRMS)
T-Cell Prolymphocytic Leukemia
Classification
Therapeutic antibody; biobetter
Patent
Blinatumomab was first received FDA approval in 2002. The patent expired in the United States in 2016.
Status
Preclinical

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Alemtuzumab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD52
Full Name
CD52 molecule
Alternative Names
HE5; CDW52; EDDM5
Gene ID
UniProt ID
Trade name
Campath, MabCampath, Lemtrada, others
Groups
Approved, Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Accession Number
DB00087 (BTD00109, BIOD00109)
CAS number
216503-57-0
Antibody Isotype
Humanized IgG1
Description
Alemtuzumab is a monoclonal antibody used to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis. It binds to CD52, a protein that exists on the surface of mature lymphocytes. In CLL, it has been used as first-line and second-line treatment. Alemtuzumab was approved for medical use in the United States in 2001.
Indication
Autoimmune Hemolytic Anemia
B-Cell Chronic Lymphocytic Leukemia
Graft Versus Host Disease (GVHD)
Kidney Transplant Rejection
Relapsing Remitting Multiple Sclerosis (RRMS)
T-Cell Prolymphocytic Leukemia
Synonyms
Not Available
UNII
3A189DH42V

Alemtuzumab is a humanized monoclonal antibody against CD52. CD52 is an antigen found on the surface of normal and malignant lymphocytes. In vitro studies have shown that Alemtuzumab has complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC) and induces apoptosis.

Autoimmune Hemolytic Anemia
B-Cell Chronic Lymphocytic Leukemia
Graft Versus Host Disease (GVHD)
Kidney Transplant Rejection
Relapsing Remitting Multiple Sclerosis (RRMS)
T-Cell Prolymphocytic Leukemia

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK